|Position||Trades||Duration||Win rate||Win/loss||Avg win||Avg loss||Return|
|Position||Trades||Duration||Win Rate||Win/Loss||Avg Win||Avg Loss||Return|
Ra Pharmaceuticals Inc (RARX)
Trading: NO POSITION @ $46.99
Signal Strength: MEDIUM
Indicator can be used in isolation but is strengthened by additional indicator confirmation. Indicator can be applied to the short or medium term timeframe and is able to highlight a potential change in price direction. This bar analysis can provide guidance on the daily battle between sellers and buyers from the companies recent trading.
Ra Pharmaceuticals Inc (NASDAQ:RARX)No bar reversal is present for Ra Pharmaceuticals Inc. Over the last 12 months there have been 6 occurrences of no bar reversals giving a signal probability of 2.3%.
PROFILE: Ra Pharmaceuticals Inc (RARX)
Stock Exchange: NASDAQ
Company: Ra Pharmaceuticals Inc
Ticker Codes: | RARX | NASDAQ:RARX |
Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system in the United States. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. Its lead product candidate is RA101495, an injection into the tissue under the skin that has completed Phase II clinical trial for the treatment of paroxysmal nocturnal hemoglobinuria (PNH); and is in Phase II clinical trial for treating patients with generalized myasthenia gravis (gMG), as well as in Phase 1b clinical trial for treating atypical hemolytic uremic syndrome (aHUS) and lupus nephritis (LN). The company's preclinical testing products include Factor D inhibition for orphan renal and dense deposit diseases, and C3 glomerulonephritis; Oral C5 inhibitor for PNH, gMG, aHUS, LN, and central nervous system (CNS) diseases; and other complement inhibitors for autoimmune/CNS diseases. It has multi-target collaboration and license agreement with Merck & Co., Inc. Ra Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Cambridge, Massachusetts.
|NVAX Novavax Inc||5.74||20.1||9,559,800||0||NEUTRAL|
|MESO Mesoblast Ads||9.39||13||403,000||0||NEUTRAL|
|LSCC Lattice Semicond||23.34||9.7||7,172,000||0||NEUTRAL|
|BLCM Bellicum Pharma||2.29||9||8,624,000||0||NEUTRAL|
|BLDP Ballard Power Systems||12.04||8.9||6,752,400||0||NEUTRAL|
|IIIN Insteel Industries||26.01||6.9||349,900||0||NEUTRAL|
|VRAY Viewray Inc||3.12||6.8||5,344,700||0||NEUTRAL|
|NNBR Nn Inc||9.97||4.6||339,800||0||NEUTRAL|
|QCOM Qualcomm Inc||95.91||4.5||23,694,300||0||NEUTRAL|